Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mohamad Bassam Sonbol"'
Autor:
Pedro Luiz Serrano Uson Junior, Umair Majeed, Jun Yin, Gehan Botrus, Mohamad Bassam Sonbol, Daniel H. Ahn, Jason S. Starr, Jeremy C. Jones, Hani Babiker, Samantha R. Inabinett, Natasha Wylie, Ashton W.R. Boyle, Tanios S. Bekaii-Saab, Gregory J. Gores, Rory Smoot, Michael Barrett, Bolni Nagalo, Nathalie Meurice, Natalie Elliott, Joachim Petit, Yumei Zhou, Mansi Arora, Chelsae Dumbauld, Oumar Barro, Alexander Baker, James Bogenberger, Kenneth Buetow, Aaron Mansfield, Kabir Mody, Mitesh J. Borad
Publikováno v:
JCO Precis Oncol
PURPOSE This investigation sought to evaluate the prognostic value of pretreatment of circulating tumor DNA (ctDNA) in metastatic biliary tract cancers (BTCs) treated with platinum-based first-line chemotherapy treatment. MATERIALS AND METHODS We per
Autor:
Timothy J. Hobday, Patrick W. McGarrah, Thorvardur R. Halfdanarson, Jennifer Gile, Rachel A. Eiring, Jason S. Starr, Mohamad Bassam Sonbol, Alex J. Liu
Publikováno v:
Pancreas. 50:500-505
Objectives Checkpoint inhibitors (CPIs) for low- and intermediate-grade neuroendocrine tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may represent promising treatment for high-grade neuroendocrine neoplasms (NE
Autor:
Amro M. Abdelrahman, Michael T. Barrett, Roberto Alva-Ruiz, Daniel H. Ahn, Nathalie Meurice, Yumei Zhou, Lewis R. Roberts, Scott I. Gamb, Heidi E. Kosiorek, Jennifer A. Yonkus, Eeva-Liisa Eskelinen, Chelsae Dumbauld, Mohamad Bassam Sonbol, Xianfeng Chen, Tanios Bekaii-Saab, James M Bogenberger, Esteban Braggio, Jennifer L. Leiting, Mark J. Truty, Marcela Salomao, Mitesh J. Borad, Bolni Marius Nagalo, Aaron S. Mansfield, Jan B. Egan, Alexander T. Baker, Pedro Luiz Serrano Uson Junior, Mansi Arora, Kenneth H. Buetow
Publikováno v:
Hepatology (Baltimore, Md.)REFERENCES. 75(1)
Biliary tract cancers (BTCs) are uncommon, but highly lethal, gastrointestinal malignancies. Gemcitabine/cisplatin is a standard-of-care systemic therapy, but has a modest impact on survival and harbors toxicities, including myelosuppression, nephrop
Autor:
Teresa Macarulla, Daniel H. Ahn, Tanios Bekaii-Saab, Chung Pin Li, Eric Van Cutsem, David Goldstein, Takuji Okusaka, Bert O'Neil, Michele Reni, Mohamad Bassam Sonbol, Josep Tabernero
Publikováno v:
Future Oncology. 15:1295-1302
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized,
Autor:
Jeanne Palmer, Mohamad Bassam Sonbol, Diana Almader-Douglas, Rafael Fonseca, Kantha R. Kolla, Tania Jain, Belal Firwana
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:239-247
Autologous stem cell transplantation (SCT) is the standard of care for all transplantation-eligible patients diagnosed with multiple myeloma (MM). Various studies have compared clinical outcomes with frontline SCT ("early SCT") versus standard-dose t
Autor:
Svetomir N. Markovic, Melanie C. Bois, Jose C. Villasboas, Rachel L. Maus, Alex J. Liu, Jason S. Starr, Sakti Chakrabarti, Chandrikha Chandrasekharan, Pashtoon Murtaza Kasi, Wendy K. Nevala, Nathan R. Foster, Mohamad Bassam Sonbol, Lionel A. Kankeu Fonkoua, Henry C. Pitot, Helen J. Ross, Tsung Teh Wu, Matthias Weiss, Rondell P. Graham, Harry H. Yoon, Haidong Dong
Publikováno v:
Int J Cancer
Through our involvement in KEYNOTE-059, we unexpectedly observed durable responses in two patients with metastatic gastroesophageal adenocarcinoma (mGEA) who received ramucirumab (anti-VEGFR-2)/paclitaxel after immune checkpoint inhibition (ICI). To
Autor:
Mohamad Bassam Sonbol, Shiv Shah, Syed Arsalan Ahmed Naqvi, Syeda A. Mina, Pedro Luiz Serrano Uson Junior, Daniel H. Ahn, Wen Wee, Tanios Bekaii-Saab, Irbaz Bin Riaz, Daniel R. Almquist, M. Hassan Murad, Zhaohui Jin, Diana Almader-Douglas, Kabir Mody, Mitesh J. Borad, Jason S. Starr, Amit Mahipal, Jehad Almasri
Publikováno v:
JAMA Oncol
Importance The treatment landscape for advanced hepatocellular carcinoma (HCC) has recently changed and become relatively confusing. Head-to-head comparisons between most of the available agents have not been performed and are less likely to be exami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c3df9d819de7b0b8d87f4d8e059ce34
https://europepmc.org/articles/PMC7582230/
https://europepmc.org/articles/PMC7582230/
Autor:
Thomas M. Habermann, Brenda Ginos, Jose F. Leis, Craig B. Reeder, Talal Hilal, Allison C. Rosenthal, Katherine Gano, Christopher R. Conley, Stephen M. Ansell, Mohamad Bassam Sonbol, Peter Leif Bergsagel, Donald W. Northfelt, Amylou C. Dueck, Heidi E. Kosiorek, Craig Nichols, Thomas E. Witzig, Patrick B. Johnston, David J. Inwards
Publikováno v:
Leukemia & Lymphoma. 59:2128-2134
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexame
Publikováno v:
Future oncology (London, England). 14(10)
Napabucasin is a novel oral first-in-class cancer stemness inhibitor. Preclinical and early phase clinical trials showed promising antitumor efficacy signals for napabucasin in a variety of malignancies. In this article, we describe the design and ra
Autor:
Mohamad Bassam, Sonbol, Belal, Firwana, Zhen, Wang, Diana, Almader-Douglas, Mitesh J, Borad, Issam, Makhoul, Ramesh K, Ramanathan, Daniel H, Ahn, Tanios, Bekaii-Saab
Publikováno v:
Cancer. 123(23)
There are limited therapeutic options for treatment-refractory pancreatic ductal adenocarcinoma (PDAC), with a paucity of data to support the best option after progression on gemcitabine-based regimens. The authors performed a meta-analysis to determ